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Abstract 
Painful diabetic peripheral neuropathy (DPN) is a common complication of diabetes. While the 
beneficial effect of exercise on diabetes has been well established, its effect specifically on painful DPN 
has not been thoroughly explored.
 
The objective of this pilot study is to examine the effect of aerobic exercise on pain in DPN.  
Methods: 
Twelve Sedentary individuals with type 2 diabetes mellitus between ages 40-70 with clinical diagnosis 
of DPN were enrolled in a 16-week, 3X week supervised aerobic exercise program. 
Brief Pain Inventory-Diabetic Peripheral Neuropathy (BPI-DPN) was used to assess pain intensity 
(worst, least, average, now) and pain interference with daily life (activity, mood, walk, normal work, 
relationship, sleep, enjoyment of life) pre and post the intervention. 
BMI, maximum oxygen uptake (VO2max), hemoglobin A1c (HbA1c), and blood pressure were also 
measured pre and post the intervention as secondary outcomes of interest. 
Results: 
10 of 12 (83.3%) (5 males/5 females; age 57 ± 4.59 years; duration of diabetes 12.2 ± 5.94 years) 
participants reported pain due to DPN on the BPI-DPN and were included in the analysis. In these 
participants, significant reductions in pain interference on walking (4.95±2.83pre/2.8±2.74post, 0.0073), 
normal work (5.3±3.16pre/3.5±3.06post, P=0.0478), relationship with others (3.55±3.62pre/1±1.15post, 
P=0.0264), and sleep (5.05±2.77pre/3.2±3.12post, P=0.0407) were observed following the intervention. 
The overall pain interference was also reduced (4.50±2.48pre/2.56±2.01post, P=0.0267). However, 
there was no change in pain intensity scores. 
iv 
VO2max showed a significant increase post-intervention, while BMI, HbA1c, and blood pressure 
remained unchanged. 
Conclusion: 
These preliminary results show reductions in perceived pain interference in people with painful DPN 
following an aerobic exercise intervention, without a change in pain intensity. Further validation by a 
randomized controlled trial is needed. 
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1 
Background 
 Introduction 
In the United States, 18.8 million people are diagnosed with diabetes and an additional 7 million 
are estimated to have undiagnosed diabetes. The estimated cost of diabetes (combined direct and 
indirect) in the United States reached an astronomical figure of $174 billion in 2007, and continues to 
steadily climb as diagnosed cases of diabetes are projected to rise to nearly 33% of all citizens by 2050 
[1]. 
Diabetic peripheral neuropathy (DPN) is a frequent complication of diabetes that affects 27-
46% of diabetic patients in the United States [2]. Also referred to as “diabetic sensorimotor 
polyneuropathy (DSPN)”, DPN is predominantly characterized by sensory symptoms in the “glove-and-
stocking” distribution [3]. Diabetes causes DPN by promoting neuronal apoptosis and inhibiting nerve 
regeneration, which leads to significant deficits in tactile sensitivity, vibration sense, lower-limb 
proprioception, and kinesthesia [4]. Some DPN patients experience painful neuropathy, characterized by 
tingling, prickling, burning, or sharp-shooting sensations typically involving the lower limb and most 
commonly the foot. Painful diabetic neuropathy (PDN) is a common phenotype of DPN that affects up 
to approximately one-third of the general diabetic population [5, 6].
 
 
Neuropathic pain due to diabetes tends to be bilateral and predominantly involves foot and in 
some cases, upper extremities including fingertips and palms [7, 8]. This distribution pattern occurs 
because the longest sensory axons are usually the first to be affected by diabetes. Pain is often worse 
during the night, as well as under stress and fatigue [6, 8]. Patients typically describe their neuropathic 
pain by using words such as “hot”, “burning”, “electric”, “jolts”, “sharp”, “tingling”, and “pins and 
needles” [8]. It may also be accompanied by allodynia (painful response to normally non-painful stimuli) 
and hyperalgesia (exaggerated response to mild pain stimuli) [7]. 
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Painful diabetic neuropathy poses a substantial and growing concern for patients and the health 
care system. PDN has been shown to be associated with significant reductions in overall quality of life 
in a cross-sectional study, where patients with PDN showed significantly poorer quality of life 
(Neuroquol questionnaire) compared to those without neuropathy and those with non-neuropathic pain 
[6]. The severity of PDN is associated with increasing levels of anxiety, depression, and sleep problems 
[9]. Painful neuropathy also causes considerable disability, with one-third of patients requiring a 
walking assist device such as a cane, walker, or wheelchair due to their neuropathy [8]. A study 
investigating gait function in type II diabetes mellitus patients with DPN found significantly greater gait 
variability and higher number of self-reported falls in DPN patients with painful neuropathy than in 
DPN patients without painful neuropathy, suggesting that pain by itself affects walking ability [10].    
The exact mechanism by which diabetes causes painful neuropathy has not been clearly 
elucidated, but increased levels of advanced glycation end products (AGE) and protein kinase C (PKC) 
due to prolonged hyperglycemia are thought to be involved in peripheral nerve damage. A cascade of 
events following the nerve damage lead to altered expression of Na+, K+, and Ca2+ channels  in the 
nociceptive neurons of the dorsal root ganglion, which causes exaggerated pain sensation [11]. Sodium 
channels also spread along the axon at the site of peripheral nerve damage and lead to ectopic neural 
discharge [11]. Pro-inflammatory cytokines including IL-6 and TNF-α are also thought to contribute to 
nerve cell damage and neuropathic pain [12]. Abnormal supraspinal modulation of sensory processing 
arising potentially due to damage from prolonged hyperglycemia may generate allodynia and 
hyperalgesia [13]. Presence of a possible genetic component in painful diabetic neuropathy has also 
been suggested [8]. 
Diagnosis and Treatment of Painful Diabetic Neuropathy 
Various methods with differing sensitivities can be used to diagnose diabetic neuropathy, 
including nerve conduction test, 10-g Semmes-Weinstein monofilament examination [SWME], 
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superficial pain sensation test, Electromyography (EMG), and several variations of vibration tests. A 
study comparing sensitivity and specificity of SWME, superficial pain sensation, vibration testing by 
the on-off method, and vibration testing by the timed method against the criterion standard of nerve 
conduction studies recommended SWME, superficial pain sensation, and vibration testing by the on-off 
method for annual screening of diabetic neuropathy in diabetes and primary care clinics, with 10g 
monofilament test as the single most practical predictor of neuropathy [14]. When diagnosing PDN, it is 
important to exclude all other etiologies of painful sensory neuropathy as diabetes patients are also at 
greater risks for conditions that may cause non-diabetic neuropathy, including chronic inflammatory 
demyelinating polyneuropathy, B12 deficiency, hypothyroidism, and uremia [15]. 
Other than proper glycemic control for management of diabetes itself, current standard care for 
treatment of PDN focuses on pharmacological treatments aiming to relieve painful symptoms. 
Commonly used drugs include, but are not limited to, tricyclic antidepressants (TCA), selective 
serotonin reuptake inhibitors (SSRI), anticonvulsants (pregabalin and gabapentin), opioids, and 
tramadol (weak opioid agonist) [7, 11, 16]. While these regimens can be effective, they are often 
expensive and result in a number of adverse side effects [11]. Some medications may worsen or trigger 
mood disorders [16]. Dose appropriate for depression may be different from that for painful neuropathy, 
thus it may be difficult to administer these drugs to diabetic patients with coexisting depression. 
Tramadol has a potential to interact with most antidepressant medications [16]. Opioids are vulnerable 
to dose escalation due to rapid development of tolerance, and may cause constipation, sweating 
abnormalities, hypogonadism, and lowered immunity [16]. α-lipoic acid treatment of PDN shows 
conflicting study results, and there are concerns that it may alter insulin sensitivity [16]. Furthermore, 
there are multiple different guidelines with conflicting information for treatment of PDN [16].  
Reviewing recent literature examining various old and new drugs for the treatment of PDN reveals that 
while a myriad of novel drugs have been introduced with many more in clinical stages of development, 
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finding appropriate pharmacologic therapies remains a strenuous effort [7]. Treatment of painful 
neuropathy continues to pose “enormous challenges” and is “currently inadequate” [11]. 
Exercise Intervention in People with Painful Diabetic Neuropathy 
Physical exercise and a healthy diet have been shown to improve management of diabetes and 
its complications [17, 18]. A single bout of exercise has been shown to improve glycemic control – as 
measured by time spent in hyperglycemia – over the following twenty-four hours in type 2 diabetic 
patients with or without insulin treatment [19]. Other studies have demonstrated that 8-16 week-long 
aerobic and resistance exercise interventions can improve functional capacity, strength, and glycemic 
control [20, 21]. A meta-analysis of twelve aerobic training studies and two resistance training studies 
(fourteen total, of which eleven were randomized controlled trials) without drug co-interventions 
observed improved levels of HbA1c, but no change in body mass [22]. This result supports the idea that 
exercise has an effect on glycemic control in diabetes that is independent from weight control. However, 
despite being recommended as a major therapeutic modality, exercise still remains underutilized [23]. 
Patients with DPN can safely engage in exercise. Previously, weight-bearing exercise had been 
contraindicated among people with DPN [24], likely due to a greater perceived risk of foot injury that 
may develop unnoticed by the patients.  However, several prospective cohort studies found no 
association between increased weight-bearing activity and risk of foot ulcers [25-27]. A following 
randomized controlled trial in 2008 showed that the intervention group who went through a self-
monitored walking program and received motivational phone calls to promote weight-bearing activities 
did not have an increased incidence of foot ulcers compared to the control group that received only 
diabetes education and foot exams [24]. This has led to a recent change in exercise guidelines for people 
with DPN to allow moderate-intensity weight-bearing exercise [28].  
Although exercise has been shown to be beneficial for diabetes control, its effects on DPN and 
especially the painful phenotype are not clear. Because poor glycemic control leading to nerve damage 
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is thought to be one of the causes of DPN, it’s possible to conjecture that exercise is protective against 
DPN. A randomized, controlled clinical trial involving diabetic patients without DPN enrolled in a 
prescribed and supervised 4-h/week exercise program for 4 years found that fewer participants in the 
exercise group developed neuropathy compared to the control group, which suggests exercise may delay 
or even prevent the onset of DPN in diabetic patients [29]. However, we cannot infer from this study 
whether exercise can reduce or reverse neuropathy in patients already affected by DPN. A mouse model 
study with four randomized groups (normal-sedentary, normal-exercise, STZ-sedentary, STZ-exercise) 
using streptozocin (STZ) to induce diabetes found that exercise training significantly decreases diabetes-
associated neuropathic pain, including thermal hyperalgesia and mechanical allodynia in diabetic mice 
[12]. Compared to the STZ-sedentary group, the STZ-exercise group showed greater expression of 
Hsp72, a heat shock protein thought to protect against cell injury and repair damaged nerves [12]. 
Hsp72 may achieve this by acting as molecular chaperones to correct protein folding, and is elevated by 
skeletal muscle contraction [12, 30]. Despite of its feasibility and potential discovered in animal models, 
exercise as a therapeutic option for painful diabetic neuropathy involving human subjects has not been 
sufficiently addressed in previous literature. 
Study Objective 
The objective of this pilot study is to explore the effect of aerobic exercise on pain in DPN. We 
hypothesize that a supervised aerobic exercise intervention can reduce painful neuropathy due to 
diabetes. 
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Research Design 
Subjects  
As a part of an ongoing pilot study investigating the effect of an exercise intervention on 
diabetic peripheral neuropathy, participants with diabetic neuropathy were recruited for this exercise 
study through flyers posted in the community and electronically via websites and email (included in 
appendix), with the goal of 20 participants completing the study. The clinicians involved in the study 
utilized their clinical records to identify potential participants. We also utilized the Frontiers Research 
Participant Registry after approval from the Data Request Committee. 
Once enrolled, participants were offered a $50 visa gift card at the midpoint (after completing 
baseline testing and the first 8 weeks of the program) and a $50 visa gift card at the completion of the 
16-week intervention and the post-intervention tests (total of $100 in gift cards) to help with 
transportation and other expenses.  
We enrolled subjects 40-70 years of age who reported a diagnosis of diabetes mellitus type II, 
with either a diagnosis of diabetic neuropathy or report of signs/symptoms consistent with neuropathy. 
In order to participate, all subjects were required to provide documentation from their physician that 
they were medically stable to participate in a supervised exercise program. The presence of neuropathy 
was confirmed with a nerve conduction testing and a clinical examination by a neurologist prior to 
enrollment. Subjects were also sedentary or under-active, as determined by a score of 5 or lower on the 
Telephone Assessment of Physical Activity (TAPA). [31] 
At baseline, we assessed neuropathic pain due to diabetes, and the overarching pilot study also 
assessed plasma insulin, glucose, and lipid levels, insulin resistance, body composition, peripheral 
autonomic nervous system function (QSART), peripheral vascular function, fatigue, executive function, 
balance / fall risk, and intra-epidermal nerve fibers (IENF) density from skin biopsy. This led to a 
7 
number of additional exclusion criteria not necessarily directly related to painful neuropathy, such as 
skin conditions or clotting disorders that would interfere with healing from the biopsy. 
Subjects were excluded if they have any of the following conditions:  
(1) Serious cardiac pathology such as recent myocardial infarction or heart surgery, uncontrolled cardiac 
arryhthmia, hypertrophic cardiomyopathy, symptomatic aortic stenosis or heart failure, unstable angina, 
acute pulmonary embolus or myocarditis, conduction abnormalities, or mitral valve prolapse;   
(2) Serious musculoskeletal problems that would limit ability to exercise;  
(3) Skin conditions, circulatory insufficiency, or open wounds in the leg that would interfere with 
healing from the biopsy;  
(4) Open wounds on the weight bearing surface of the feet; 
(5) Not able to ambulate independently;  
(6) Stroke or other central nervous system pathology;  
(7) Stage 2 hypertension (resting blood pressure > 160 systolic or > 100 diastolic);  
(8) Lidocaine allergy;  
(9) Anticipated difficulty with blood clotting due to Coumadin (Warfarin) use or blood clotting disorder;  
(10) Body weight > 450 lbs;  
(11) Inadequate cognition and communication abilities, defined as < 24 on the Mini Mental Status Exam 
(MMSE); or 
(12) Pregnant or planning on becoming pregnant in the 18 weeks following enrollment. 
The inclusion and exclusion criteria were reviewed with a phone screen (included in appendix) 
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prior to scheduling the initial visit. During the initial visit, prior to signing informed consent, the 
inclusion/exclusion criteria were confirmed via medical history, medication review, resting vital signs, 
Michigan Neuropathy Screening Instrument (MNSI -- includes visual exam of legs and feet), weight 
and height measures, and MMSE. After consent but prior to enrollment, participants completed the 
nerve conduction studies and quantitative sensory testing to confirm the presence of diabetic neuropathy, 
and participants also completed the graded maximal exercise test to confirm their ability to exercise 
safely. For female pre-menopausal subjects, a urine pregnancy test was completed prior to enrollment. 
Once enrolled, a letter was sent to the participant’s primary care physician (included in 
appendix) to inform them of the study procedures and inclusion/exclusion criteria. 
Testing Schedule 
Aerobic fitness was assessed with a graded maximal exercise test with a metabolic cart (Parvo 
Medics TrueOne 2400) and integrated ECG, using a standardized protocol with the total body 
recumbent stepper (TBRS, Nustep) for the exercise test [32, 33] approximately a week before the 
beginning of each subject’s intervention program. We used the maximal workload obtained from this 
test as an outcome measure and also to calculate a moderate level of intensity and corresponding target 
heart rates (50-70% of VO2 reserve) for the aerobic training program. 
The graded maximal exercise test and assessment of outcome measures were completed 
primarily in the Clinical and Translational Science Unit (CTSU) in Kansas City, KS at baseline and 
following the 16-week intervention by study personnel and CTSU staff. A comprehensive testing 
schedule for each participant is described in Table 1. 
Table 1: Participant Visit Schedule 
 Before initial visit Phone screening form with TAPA 
Visit 1: CTSU  
(~ 3 hours, ~1 week before 
beginning intervention) 
Pre-consent  
(1 hour)  
Confirm inclusion/exclusion screening criteria 
Consent  
(30 min) 
Informed consent review and signature  
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Post-consent prior 
to enrollment  
(1 ½ hours) 
Pregnancy test (if indicated) 
Nerve conduction studies  
Quantitative sensory testing 
Aerobic fitness via graded maximal exercise test 
Visit 2: CTSU  
(~ 1 ½ hours, ~1 week 
before beginning 
intervention) 
Post-enrollment Blood draw (Fasting)  
*Snack provided  
Q-Sweat test  
iDXA scan  
Skin biopsy  
Questionnaires to take home (Pain, Fatigue, Fall 
history, DHI, ABC scale) 
Visit 3: Georgia Holland 
REACH lab, G002 
Hemenway 
(~ 1 ½ hours, ~2-3 days 
before beginning 
intervention) 
 *Retrieve questionnaires 
Peripheral vascular scan (Fasting) 
*Snack provided (glucose check) 
Executive function tests 
Balance tests 
Intervention in Georgia Holland HEAL lab, G006 Hemenway 
Visit 4: REACH lab 
(~ 1 ½ hours, ~2-3 days 
after the intervention end) 
Post-intervention Peripheral vascular scan (Fasting) 
*Snack provided 
Executive function tests 
Balance tests 
Questionnaires to take home (Pain, Fatigue, Fall 
history, DHI, ABC scale) 
Visit 5: CTSU 
(~ 2  ½ hours, ~1 week after 
the intervention end) 
Post-intervention *Retrieve questionnaires 
Medication review, resting vital signs, MNSI, 
weight and height 
Nerve conduction studies  
Quantitative sensory testing 
Aerobic fitness via graded maximal exercise test  
Skin biopsy 
Visit 6: CTSU 
(~ 1 ½ hours, ~1 week after 
the intervention end) 
Post-intervention Blood draw  
*Snack provided  
Q-Sweat  
iDXA scan 
TAPA = telephone assessment of physical activity; DXA = dual-energy X-ray absorptiometry; DHI = 
Dizziness Handicap Inventory; ABC Scale = Activities Balance Confidence Scale 
Intervention 
Subjects participated in 16 weeks of supervised aerobic exercise 3 times each week. Duration of 
the sessions progressed from 30 to 50 minutes and vital signs were closely monitored. The intensity of 
the aerobic activity was individually prescribed based on heart rate response during the graded maximal 
exercise test (progressing from 50 to 70% of VO2max reserve), as shown in Table 2. 
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Participants were given an option to select from a variety of aerobic training equipment 
available in the Georgia Holland Health Exercise and Aging Lab in University of Kansas Medical 
Center, including cycle ergometers, treadmills, recumbent steppers, and elliptical trainers. The format of 
the aerobic exercise program was modified based on our previous experience to include only aerobic 
activities, with frequency, intensity, duration, and progression within the updated American College of 
Sports Medicine (ACSM) Guidelines [34], Joint Position Statement on Exercise and Type 2 Diabetes 
(ACSM and ADA,[35]), and ADA Standards of Medical Care (2012)[36]. Each exercise session started 
with brief stretching and/or a 5-minute warm up period, and finished with a 5-10 minute cool down 
period. 
Resting blood pressure, heart rate, and rate of perceived exertion (RPE) were monitored for 
every subject before, during, and following the aerobic activity. A visual foot exam was performed each 
week to ensure absence of developing foot ulcers. Blood glucose check was performed on all 
participants prior to each exercise session according to recently updated ADA guidelines (2012): 
*If hypoglycemic (<100 mg/dL), carbohydrates were provided and the participant proceeded to exercise 
if hypoglycemia resolved with retesting. 
*If hyperglycemic (> 300 mg/dL) and participant was not on insulin, exercise was permitted with close 
monitoring of blood glucose every 10-15 minutes. If blood glucose rose with activity, exercise was 
stopped. 
*If hyperglycemic (> 300 mg/dL) and the participant was taking insulin, urine was checked for ketosis. 
If positive for ketones, exercise was postponed. If negative for ketones, exercise was permitted with 
close monitoring of blood glucose every 10-15 minutes. 
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Table 2: Aerobic Exercise Intervention Schedule 
WEEK Day 1 Day 2 Day 3 
1 50% VO2R, 30 min 50% VO2R, 30 min 50% VO2R, 35 min 
2 50% VO2R, 35 min 50% VO2R, 35 min 50% VO2R, 40 min 
3 50% VO2R, 40 min 50% VO2R, 40 min 50% VO2R, 45 min 
4 50% VO2R, 45 min 60% VO2R, 45 min 60% VO2R, 45 min 
5 60% VO2R, 45 min 60% VO2R, 45 min 60% VO2R, 45 min 
6 70% VO2R, 45 min 70% VO2R, 45 min 70% VO2R, 45 min 
7 70% VO2R, 50 min 70% VO2R, 50 min 70% VO2R, 50 min 
8 - 16 70% VO2R, 50 min 70% VO2R, 50 min 70% VO2R, 50 min 
 
Primary Outcome Assessment 
Painful neuropathy was measured using the Brief Pain Inventory Short Form for Diabetic 
Peripheral Neuropathy (BPI-DPN). This scale has been specifically validated in this population [37, 38], 
and consists of 4 pain intensity items (worst, least, average, and current pain severity) and a 7-item pain 
interference scale (impact of diabetic neuropathic pain on quality of life, described by general activity, 
mood, sleep, walking ability, relationships, and enjoyment of life). Overall interference with life by 
painful neuropathy from DPN was assessed by the average of the 7 interference items. The entire 
questionnaire took approximately 5-10 minutes to complete for each participant. 
 
Secondary Outcome Assessment 
Each participant’s BMI, aerobic fitness (indicated by VO2max), blood pressure, and glycemic 
control (indicated by Hemoglobin A1c) were measured as secondary outcomes of interest. Pre and post 
the exercise intervention. 
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Documentation of AEs 
During each study visit (testing session or exercise session), subjects were asked about adverse 
events, including falls, change in medical status, or problems that resulted from study procedures. Any 
adverse events that occurred during the testing or exercise sessions were documented. An AE form 
(included in Appendix) was utilized to help classify these events as follows: 
 Related to study procedure as determined by the PI or unrelated to study procedure (related 
instead to underlying disease, pre-existing conditions, or other factors) 
 Anticipated (included in consent form) or unanticipated (not included in consent form 
 Serious (SAE, Grade 4 using CTCAE v3.0) or not serious (AE, Grade 1, 2 or 3 using CTCAE 
v3.0) 
Any AEs that were related to study procedures, unanticipated, or serious were reported to the 
medical monitor and to the Human Subjects Committee (HSC). A report that summarizes the frequency 
of all AE’s was provided to the medical monitor on a quarterly basis. 
Statistical Analysis 
All pre vs post outcome comparisons, including BPI-DPN intensity, BPI-DPN interference,  BMI, 
VO2max, blood pressure, and Hemoglobin A1c were analyzed with matched-pair t-test using JMP
®
 Pro 
9.0.2. 
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Results 
Subject Enrollment and Baseline Characteristics 
72 people were contacted and screened, of whom 37 people met the eligibility (Figure 1). 12 of 
37 eligible people declined to participate. Of the remaining 25 people, 8 could not participate due to one 
of the following reasons: abnormality detected during the baseline exercise test, absence of neuropathy 
in the nerve conduction and sensory testing, unstable hyperglycemia (blood glucose > 300 mg/dL and 
positive ketone test) during the first screening visit, AE unrelated to the study prior to starting 
intervention, and scheduling conflicts. As a result, 17 people were able to start the exercise program. As 
of 4/1/2013, 10 participants have completed their intervention as well as pre and post outcome 
assessments. These 10 participants had an average exercise completion rate of 81.9 ± 10.1%. The 
baseline measurements of the 10 participants are shown in Table 3. 6 additional participants are 
scheduled to complete the study by June 2013.  
 
Figure 1: Flowchart of Subject Recruitment and Enrollment 
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Table 3: Baseline measurements 
Age 57 ± 4.59 years 
Years with Diabetes 12.2 ± 5.94 years 
Race White (40%)/African-American (30%)/Hispanic (30%) 
Years with DPN 7.2 ± 3.77 years 
HbA1c 7.96 ± 2.32 % 
Systolic Blood Pressure 130.6 ± 15.82 mmHg 
Diastolic Blood Pressure 74.7 ± 10.48 mmHg 
Gender Male (50%)/Female (50%) 
Insulin Use Yes (80%)/No (20%) 
 
Primary Outcome Variables 
Pain intensity ratings at baseline (Worst=5.45, least= 3.65, average=3.95, now=3.35, mean of 
four items=4.1) were similar or somewhat lower compared to results found in a previous study that 
validated BPI-DPN (Worst=5.5, least=4.0, average=5.0, now=4.4, mean of four items=4.7)[38], and 
another study assessing burden of illness associated with painful diabetic neuropathy using BPI-DPN 
(mean of four items=5.0)[39]. Pain interference ratings at baseline (General activity=3.8, Mood=4.0, 
Walking=4.95, Normal work=5.3, Relationship=3.55, Sleep=5.05, Average interference=4.5) were also 
similar or slightly lower than results from the BPI-DPN validation study (General activity=4.7, 
Mood=4.9, Walking=5.6, Normal work=5.3, Relationship=3.7, Sleep=5.2, Average interference=4.9) 
[38], and the burden of illness study (Average interference=5.0) [39]. 
Despite an overall downward trend, there was no statistically significant change in any of the 
pain intensity items (Figure 2) (Table 4). There were significant reductions in 4 of the 7 pain 
interference items (Figure 3), including walking (p=0.0073), normal work (p=0.0478), relationship with 
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others (p=0.0264), and sleep (p=0.0407), while the remaining 3 items (general activity, mood, 
enjoyment of life) did not change. Average of the 7 pain interference items was also significantly 
reduced after the exercise intervention program (p=0.0267). 
 
Figure 2: Changes in BPI-DPN Pain Intensity Items 
There were small, non-significant reductions in each of the four perceived pain intensity items (worst, 
least, average, now) by the participants after the completion of 16-week aerobic exercise intervention.  
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Figure 3: Changes in BPI-DPN Pain Interference Items 
(GA=General activity, NW=Normal work, Relations=Relationship with others, Enjoyment=Enjoyment 
of life, Avg=Interference average). Interference by painful neuropathy due to diabetes on walking, 
normal work, relationship with others, and sleep showed significant reductions post-intervention, while 
interference by painful neuropathy due to diabetes on general activity, mood, and enjoyment of life 
showed statistically non-significant, but potentially clinically important reductions. Overall interference 
(average of the 7 interference items) rating was also reduced significantly. * denotes p<0.05. 
 
Table 4: BPI-DPN Pain Intensity Outcome 
 Pre-Intervention Post-Intervention Change P-value 
Pain Intensity (Worst) 5.45±1.86 5.0±2.36 -0.45±2.50 0.58 
Pain Intensity (Least) 3.65±1.92 2.6±1.84 -1.05±2.31 0.19 
Pain Intensity (Average) 3.95±1.46 3.2±1.93 -0.75±2.23 0.31 
Pain Intensity (Now) 3.35±1.73 2.3±1.83 -1.05±2.31 0.19 
 
 
* 
* 
* 
* 
* 
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Table 5: BPI-DPN Pain Interference Outcome 
 Pre-Intervention Post-Intervention Change P-value 
General Activity 3.8±2.30 2.1±2.28 -1.7±3.02 0.11 
Mood 4±2.91 2.5±1.65 -1.5±3.50 0.21 
Walk 4.95±2.83 2.8±2.74 -2.15±1.97 0.0073* 
Normal Work 5.3±3.16 3.5±3.06 -1.8±2.49 0.0478* 
Relationship with Others 3.55±3.62 1±1.15 -2.55±3.04 0.0264* 
Sleep 5.05±2.77 3.2±3.12 -1.85±2.45 0.0407* 
Enjoyment of Life 4.85±3.20 3±3.30 -1.85±3.42 0.12 
Average 4.50±2.48 2.56±2.01 -1.94±2.34 0.0267* 
*Denotes significant changes 
  
 
Secondary Outcome Variables 
 A small, non-significant reduction in BMI was observed after the intervention (-0.523 
kg/m
2
±1.27, p=0.23) (Table 6). Both systolic and diastolic blood pressure showed non-significant 
increases (Systolic: +6.5±13.13mmHg, p=0.15, Diastolic: +2.9±8.24mmHg, p=0.29), while Hemoglobin 
A1c remained essentially identical (-0.06±0.79%, p=0.82), suggesting that the participants did not 
benefit in their glycemic control from the exercise program. However, the participants’ aerobic fitness, 
as measured by their VO2max, showed a moderate (8.6%), statistically significant (p=0.04) improvement.  
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Table 6: Changes in Secondary Outcomes 
 Pre-Intervention Post-Intervention Change P-value 
BMI 34.96±5.05kg/m
2
 34.43±5.32kg/m
2
 -0.523±1.27kg/m
2
 0.23 
VO2max 16.21±4.40ml/kg/min 17.6±4.71ml/kg/min 1.39±1.85ml/kg/min 0.04* 
Blood Pressure (Systolic) 130.6±15.82mmHg 137.1±11.53mmHg 6.5±13.13mmHg 0.15 
Blood Pressure 
(Diastolic) 
74.7±10.48mmHg 77.6±9.56mmHg 2.9±8.24mmHg 0.29 
HbA1c 7.96±2.32% 7.9±2.11% -0.06±0.79% 0.82 
*Denotes a significant change 
 Adverse Events 
No Grade 3 or Grade 4 adverse events (AE) occurred during screening and testing sessions or 
intervention. Grade 2 AE’s (clinical symptoms that required minimal, non-invasive intervention) 
consisted of episodes of transient hypoglycemia (BG < 100 mg/dL) after exercise, which were shortly 
resolved with administration of carbohydrates, hyperglycemia (BG > 300 mg/dL) with positive ketone 
test, mild joint discomforts, muscle cramp, fatigue, and transient hypertension at rest. 
One participant developed knee swelling with pain during the intervention period. This 
participant was referred to an orthopedist and recovered without needing surgery, but decided to stop the 
intervention at this point. Another participant developed a unilateral dorsal foot swelling with mild pain 
after an active day at home, after which the participant’s physician was contacted, and the exercise 
intervention was halted. After examination, the physician concluded that the participant could return to 
exercise after a brief period of resting, and the participant completed the intervention without any 
further related AE’s. This participant’s data was not included in the analysis. 
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Discussion 
The results imply that while the participants’ perceived pain intensity from DPN did not change, 
they felt less hindered in certain aspects of their life by the painful neuropathy after the 16-week 
exercise intervention. It is also possible that the non-significant reductions in pain severity items could 
not be detected due to our limited sample size, but are still clinically important. 
Our findings show significant reductions in how the participants felt their diabetic neuropathic 
pain interfered with their daily activities including walking, normal work, relationships with others, and 
sleep. A significant reduction in average pain interference scale reveals that the intervention was 
successful in abating the impact of pain on quality of life. Absence of significant changes in pain 
intensity suggests that the decrease in neuropathic pain interference may be psychological. The 
participants may be experiencing less overall distress in, walking, normal work, relationship with others, 
and sleep despite persisting pain. It is also possible that the participants learned to cope better with their 
neuropathic pain. On the other hand, the fact that all four of the pain intensity items showed modest, 
non-significant decreases points to another possibility that our sample size was simply too small to 
detect a potentially clinically important improvement in perceived pain. 
A minor, non-significant decrease in average BMI supports a meta-analysis of clinical trials 
involving 12-week to 12-month duration exercise programs, which concluded aerobic exercise alone is 
not an effective weight loss therapy [40]. However, our hemoglobin A1c results do not agree with 
findings of previous studies that showed exercise was beneficial for improving glycemic control as 
indicated by reductions in HbA1c levels [19-22].  The reason for this is unclear. The participants’ 
overall aerobic fitness improved, showing that they still benefited from the intervention although they 
did not lose weight. These secondary outcome findings also imply that the reduction in pain interference 
could be independent of weight loss and glycemic control.  
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The exercise compliance rate of our participants (81.9%) was comparable to the average rate 
found in a meta-analysis of 27 exercise studies for type 2 diabetes mellitus patients (86%) [41]. Our 
slightly lower number may be attributed to the fact that only 12 of the 27 studies actually declared their 
compliance rate. The meta-analysis also included studies involving aerobic, resistance, and aerobic-
resistance training rather than just aerobic exercise. Furthermore, frequencies, durations, eligible subject 
profile (Presence of DPN was necessary to participate in our study) and exact protocols of these studies 
were different. We believe that the exercise compliance rate in our study and the fairly low drop-out rate 
(1 out of 13 participants) support the idea that regular exercise intervention is feasible in people with 
painful DPN. 
At baseline, the participants reported experiencing slightly lower levels of pain intensity and 
pain interference due to DPN compared to previous studies using BPI-DPN to assess pain in painful 
DPN patients. These differences may be attributed to a selection bias in our study because people with 
very severe diabetic complications were likely either excluded because they did not meet the 
inclusion/exclusion criteria, or declined to participate partially due to being in poor physical shape.  
Another possible explanation for the difference is that the previous studies included both type 1 and type 
2 diabetes mellitus patients, while our study only enrolled type 2 patients. This leads to a potential 
limitation in generalizability. Because our subject pool only included participants who were physically 
able to do moderate intensity aerobic exercise, patients with severe, longstanding diabetes or patients 
with significant co-morbidity such as cardiac disease were excluded. The idea that our subject pool 
cannot be generalized to patients with severe diabetes is supported by the average HbA1c level of our 
participants at baseline (7.96%), which was approximately one percent below what would be considered 
by CDC as “poorly controlled diabetes” [1].  The subjects in our study also gave informed consent to 
participate in a three-times-a-week, 16 week-long exercise program, which would suggest that despite 
being previously sedentary, they may have been more motivated to improve their health compared to the 
general diabetic population. However, we believe that our findings are still significant because with the 
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enormous, growing prevalence of diabetes and DPN, even after excluding patients who physically 
cannot or are not willing to exercise regularly, a large population would be able to benefit from the 
exercise programs. 
 
 
 
Conclusion 
These preliminary results show reductions in perceived pain interference in people with painful DPN 
following an aerobic exercise intervention, without a change in pain intensity. The intervention also 
improved VO2max in our participants, but did not lead to changes in BMI, HbA1c, and blood pressure. 
We feel that the natural extension of our pilot data should be a follow-up randomized controlled trial 
with a larger sample size for further validation.  
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Appendix A: Recruitment Flyer 
 
 
 
  
25 
Appendix B: 30-Second Radio Script for Recruitment 
 
If you or someone you know has diabetes and has problems with pain or 
numbness in their feet, then you may be interested in a research study that is 
being conducted at the University of Kansas Medical Center. I’m Dr. Patricia 
Kluding, a physical therapist and researcher at KU Med, urging you to contact us 
at 913-945-6630 to see if you would be eligible to participate in this exercise 
study.  
 
There will be no cost to you or your insurance company for these supervised 
exercise sessions or other expenses related to the study.   If you have diabetes and 
pain or numbness in your feet, pick up the phone and call us at 913-945-6630.    
 
You deserve to get the most out of life. Take charge of your diabetes.  
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Appendix C: Phone Screening Form 
PHONE SCREENING  
Exercise and Neuropathy Research Group version 2 (ENRGy2) Project 
 
Greetings: “We are conducting a study to see if exercise will improve nerve function in people with 
diabetes who have problems with their nerves in the legs and feet. The exercise sessions are 3 days per 
week for 16 weeks here at KUMed. May I have your permission to ask you some preliminary questions 
to see if you may be eligible for the study?” 
 
If yes: 
Name  
Date of contact  
 
If criteria is not met for any of the following items: “I am sorry you do not meet the entry criteria for 
this study. Thank you for calling.” 
 
Do you have diabetes?  If yes, continue 
Do you have neuropathy or 
symptoms of numbness, pain or 
tingling in the feet? 
 If yes, continue 
How old are you?  If between 40 and 70, continue 
Have you been hospitalized with a 
heart attack or heart surgery in the 
preceding 3 months? 
 If no, continue 
Do you have any other serious heart 
problems?  
 If no, continue  
Have you had any chest discomfort 
(pressure or pain) in the last 3 
months? 
 If no, continue 
Do you have any bone, joint, or 
muscle problems that limit your 
 If no, continue 
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ability to exercise?   
If yes, please describe. 
Do you have any open wounds on 
the soles of your feet? 
 If no, continue  
Can you walk without anyone 
helping you?  
(cane, walker, leg brace is ok)  
 If yes, continue 
Have you ever had a stroke or other 
disease of the brain or nervous 
system?   
(Examples: multiple sclerosis, 
Parkinson’s disease) 
 If no, continue 
What is your blood pressure?     If systolic < 160 and diastolic 
<100, or if unknown, continue 
Are you allergic to Lidocaine?    If no, continue 
What is your current weight?  
 
If <450 lbs. continue 
 
Do you use Coumadin or have a 
clotting disorder 
 If no, continue 
Are you currently pregnant or plan 
on becoming pregnant in the next 
18 months? 
 
 
If no, continue 
 
Is there anything else we need to 
know about you or your medical 
history? 
  
 
Telephone Assessment of Physical Activity 
 
I am going to ask you about the amount and level of physical activity you usually do. In this survey, we 
define physical activities as activities where you move and increase your breathing or heart rate. These 
are activities you do for pleasure, work, or for getting around. I will read a statement about activities, 
and you can tell me whether the statement describes you by answering yes or no or not sure 
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The first statement is: 
 
 
 
 
The next statements are about three types of activities: light, moderate, and vigorous. Light activities are 
activities when your heart beats only slightly faster than normal and you can still talk and sing during 
them. Some examples of light activities are walking leisurely, light vacuuming, light yard work, or light 
exercise such as stretching. Here are two statements about light activity, 
 
 
 
Next are moderate activities. Moderate activities are activities when your heart beats faster than normal. 
You can still talk but not sing during such activities. Some examples of moderate activities are fast 
walking, aerobics class, strength training, or swimming gently. I have four statements about moderate 
activities. The first one is, 
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If yes to #6: “I am sorry you do not meet the entry criteria for this study. Thank you for calling.” 
 
If no to #6:  continue 
 
The next three statements are about vigorous activities. Vigorous activities are activities when your 
heart rate increases a lot. You typically can’t talk or your talking is broken up by large breaths. Some 
examples of vigorous activities are jogging, running, using a stair machine, or playing tennis, 
racquetball, badminton 
 
 
If yes to #7: “I am sorry you do not meet the entry criteria for this study. Thank you for calling.” 
If no to #7:  continue on next page 
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If interested in study and meet criteria, collect additional information: 
 
Phone Number (home / cell / work)  
Address  
 
Email Address 
 
 
Preferred mode for sending directions and 
other information   
(mailing address or email) 
 
Contact Person (if desired)  
Birthdate 
 
 
Unique Subject Code   
Testing session 1: Date/ time 
 
 
Testing session 2: Date/ time 
 
 
Testing session 3: Date / time  
Preferred days and time for exercise program 
 
 
 
 
Name of person completing this form ________________________________________  
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Appendix D: Physician Letter 
[insert date] 
Dear [insert Physician/Health Care Provider’s name], 
Your patient [insert name, date of birth] would like to participate in a research project at the University of Kansas 
Medical Center, “Pilot Study of Exercise and Peripheral Nerve Function in People with Diabetes” (Human 
Subjects Committee approval # 11385 and CTSU approval # 105). This project involves a graded maximal 
exercise test and a supervised 16-week aerobic exercise program.  
The purpose of this research study is to determine the effect of an aerobic exercise intervention on nerve function 
in people with diabetic peripheral neuropathy, including assessment  of changes in cutaneous innervation, vascular 
and metabolic outcomes, body composition, and other outcome measures.  
We have reviewed your patient’s medical history and list of current medications to confirm the absence of 
pathological conditions that would be a contraindication to exercise in your patient. Your patient has completed a 
graded maximal exercise with ECG monitoring and a metabolic cart to confirm their ability to exercise safely and 
to determine their level of aerobic fitness to prescribe an appropriate exercise intensity. During all exercise 
sessions, we will monitor blood glucose, heart rate, and blood pressure.  
We will be recruiting up to 30 participants with diabetic peripheral neuropathy for this study, age 40-70. In 
addition to receiving supervised exercise sessions without cost, subjects will be given a total of $100 in gift cards 
once the study is completed. I would be happy to answer any questions you may have about the study, and please 
let me know if you have any specific concerns regarding your patient. 
 
Sincerely, 
 
Patricia Kluding PT PhD 
Associate Professor, Department of Physical Therapy and Rehab Science 
913-588-6918 or pkluding@kumc.edu  
 
Linda D’Silva, PT 
Study Coordinator  
913-945-6630 or ldsilva@kumc.edu  
 
Georgia Holland Health Exercise and Aging Lab 
Department of Physical Therapy and Rehabilitation Science 
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Appendix E: Adverse Event Form  
ADVERSE EVENT FORM 
ENRGy2 STUDY 
Subject ID: ___________________  Date: _________________________ 
Information gathered in person or via phone or email? _________________ 
Brief Description of Adverse Event and Action Taken: 
 
 
 
 
 
 
Is AE related to study procedures?   □ Yes □No 
 Comment: 
Is AE anticipated from risks described in consent form? □ Yes □No 
 Comment:  
Is AE severity:  □ Mild (asymptomatic, transient) 
□ Moderate (symptomatic, interferes with function, requires treatment)  
□ Severe (disabling, life-threatening, requires hospitalization) 
 Comment: 
 
*If AE is moderate or severe, notify study coordinator and PI immediately. 
*Use additional paper to continue with comments or to follow up as indicated. 
Person completing form: __________________________________ 
Signature: ________________________________ Date: __________________ 
 
